• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

    11/7/24 9:24:55 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STTK alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 SHATTUCK LABS INC COMMON STOCK Cusip #82024L103 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #82024L103 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 131,816 Item 6: 0 Item 7: 134,543 Item 8: 0 Item 9: 134,543 Item 11: 0.281% Item 12: HC Cusip #82024L103 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 134,543 Item 8: 0 Item 9: 134,543 Item 11: 0.281% Item 12: IN Item 1(a). Name of Issuer: SHATTUCK LABS INC Item 1(b). Address of Issuer's Principal Executive Offices: 500 W. 5TH STREET Austin, TX 78701 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 82024L103 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 134,543 (b) Percent of Class: 0.281% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 134,543 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of SHATTUCK LABS INC. No one other person's interest in the COMMON STOCK of SHATTUCK LABS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 6, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 6, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of SHATTUCK LABS INC at October 31, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $STTK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STTK

    DatePrice TargetRatingAnalyst
    3/17/2025$4.00Outperform
    Leerink Partners
    10/2/2024$8.00 → $2.00Buy → Neutral
    Citigroup
    10/2/2024Buy → Hold
    Needham
    10/1/2024Buy → Neutral
    H.C. Wainwright
    6/17/2024Buy → Neutral
    BTIG Research
    8/31/2022$12.00Buy
    BTIG Research
    6/1/2022$13.00Buy
    Citigroup
    5/2/2022$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $STTK
    Financials

    Live finance-specific insights

    See more
    • Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

      – Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued –   – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025 – – SL-172154 associated restructuring expected to extend cash runway into 2027 – – Company to host investor call today at 8:00 AM Eastern Time (ET) – AUSTIN, T

      10/1/24 6:30:00 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

      – Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA – – Focuses clinical development opportunity in HR-MDS and TP53m AML; these indications may offer the fastest path to potential approval; enrollment underway in randomized, controlled HR-MDS co

      6/14/24 6:00:00 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

      - Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the EHA 2024 Congress. The event will feature lead investigator, Dr. Naval G. Dave

      6/6/24 7:30:00 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, May 01, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025 and provided recent business highlights. "All IND-enabling activities and regulatory interactions rem

      5/1/25 4:20:00 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

      AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025. Conference DetailsFormat: Presentation and one-on-one meetingsPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive OfficerDate: April 9, 2025Time: 3:00 PM EDTWebcast link: HERE A

      4/2/25 5:00:00 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

      – Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism – – SL-325 advances toward Phase 1; on track for IND filing in the third quarter of 2025 – – Cash balance of approximately $73.0 million as of December 31, 2024, expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, March 27, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneerin

      3/27/25 7:00:00 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Redmile Group, Llc sold $166,714 worth of shares (133,371 units at $1.25), bought $166,714 worth of shares (133,371 units at $1.25), disposed of $1,283,610 worth of shares (1,026,888 units at $1.25) and acquired $1,283,610 worth of shares (1,026,888 units at $1.25) (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      12/6/24 9:00:15 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Schreiber Taylor bought $44,220 worth of shares (36,500 units at $1.21), increasing direct ownership by 106% to 71,002 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      10/8/24 6:05:12 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Brous Tyler bought $32,768 worth of shares (8,416 units at $3.89), increasing direct ownership by 4% to 238,088 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      7/1/24 6:30:02 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $STTK
    SEC Filings

    See more

    $STTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $STTK
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

      SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

      12/6/24 9:03:38 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

      SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

      11/13/24 8:30:26 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

      SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

      11/12/24 5:01:20 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Shattuck Labs Inc.

      10-Q - Shattuck Labs, Inc. (0001680367) (Filer)

      5/1/25 4:28:54 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Shattuck Labs, Inc. (0001680367) (Filer)

      5/1/25 4:21:31 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Shattuck Labs Inc.

      10-K/A - Shattuck Labs, Inc. (0001680367) (Filer)

      5/1/25 4:14:05 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Shattuck Labs with a new price target

      Leerink Partners initiated coverage of Shattuck Labs with a rating of Outperform and set a new price target of $4.00

      3/17/25 7:44:03 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs downgraded by Citigroup with a new price target

      Citigroup downgraded Shattuck Labs from Buy to Neutral and set a new price target of $2.00 from $8.00 previously

      10/2/24 7:58:39 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs downgraded by Needham

      Needham downgraded Shattuck Labs from Buy to Hold

      10/2/24 7:40:05 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

      AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre

      3/4/24 7:00:00 AM ET
      $IMNM
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

      AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023. Title: Shattuck Labs Third-Quarter 2023 Earnings Call Speakers: Taylor Schreiber, CEO; Andrew Neill, CFO; Lini Pandite, CMO Date & Time: Thursday, November 9, 2023 at 8:00 a.m. ET Dial-in Details: Toll-Free Dial-In Number: 1 (888) 440-4368 To

      11/6/23 9:28:40 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Announces Changes to its Board of Directors

      AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced the appointment of Dr. Carrie Brownstein, M.D., to its Board of Directors. Dr. Brownstein currently serves as the Chief Medical Officer at Cellectis. She will replace Josiah Hornblower, Shattuck's Chairman and founder, who is stepping down from the Board of Directors. George Golumbeski, Ph.D., has been appointed Chairman of the

      10/28/21 4:30:00 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technical Officer Shukla Abhinav A. covered exercise/tax liability with 2,261 shares, decreasing direct ownership by 3% to 73,536 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      1/28/25 6:13:29 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business Officer Deyoung Casi covered exercise/tax liability with 2,297 shares, decreasing direct ownership by 3% to 81,465 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      1/28/25 6:08:41 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Pandite Arundathy N. covered exercise/tax liability with 3,211 shares, decreasing direct ownership by 2% to 206,265 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      1/28/25 6:04:53 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care